Andrew Chang’s Post

Excited by the idea of #generative biology. Generative AI has moved beyond writing poems and drafting emails. Now its being used to generate novel proteins - #DNA sequences never before seen in nature. This means medicines can be designed to fit a specific target. This dramatically increases success rates and cuts drug development timelines. Generative Biologics could be the next wave of new therapeutics. #GenAI #drugdiscovery #pharma #investing #equities https://lnkd.in/eWxQvZRt

Excited by the idea of #generative biology. Generative AI has moved beyond writing poems and drafting emails. Now its being used to generate novel proteins - #DNA sequences never before seen in nature. This means medicines can be designed to fit a specific target. This dramatically increases success rates and cuts drug development timelines. Generative Biologics could be the next wave of new therapeutics. #GenAI #drugdiscovery #pharma #investing #equities https://lnkd.in/eWxQvZRt

As a young biopharmaceutical startup specializing in #DNA and #peptideengineering technologies, we are thrilled to announce the advancement of our groundbreaking product, TheraVac-AA-1, into the #preclinical studies stage. This milestone underscores the collaborative efforts of TheraVac Biotech & its partners in pioneering innovative therapies focused on cellular #longevity & #antiaging. About TheraVac-AA-1: TheraVac-AA-1 is a #novel #peptide designed to target two key proteins within the 6-component #shelterincomplex, responsible for telomere protection and cellular stability. By enhancing interactions within this complex, TheraVac-AA-1 aims to support telomere integrity and help combat age-related cellular decline. After rigorous #insilico validation, the peptide is ready for synthesis and in vivo preclinical testing. Transition to Preclinical Studies: Following the successful design and computational validation phase, TheraVac-AA-1 will now enter in vivo preclinical studies, where its safety, efficacy, and potential to regulate telomerase activity will be evaluated. This is a critical step in bringing our anti-aging therapy closer to reality. Exploring Collaborations: As we move forward with TheraVac-AA-1, TheraVac is actively seeking partnerships with life science sponsors to accelerate development and expand the scope of this promising therapeutic. Collaborations with new partners will be key in driving the development of TheraVac-AA-1. Looking Ahead: TheraVac remains committed to advancing cutting-edge therapies through rigorous scientific evaluation & collaboration with partners in the #tech & #lifesciences fields. Stay tuned for further updates as we continue toward preclinical trials, with TheraVac-AA-1 offering exciting potential in the field of anti-aging and cellular health. Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Caroline Rodriguez Samuel Craft Raphael Wenninger TeslaDuo Technologies TradePharma Network TradePharmaDAO OmniversalisDAO Sirrena BayesLearn Systems #Biotechnology #Innovation #DrugDiscovery #AI #Sirrena #BayesLearnSystem #cellularhealth #PeptideEngineering #PrecisionMedicine #Telomeres #IPprotection #NFT #Discoveria #TokenZu #TheraVac

In progress at TheraVac Biotech: 1️⃣ 4 biologic compounds: - One #anticancer: TheraVac-TNBC-1. A novel peptide vaccine. - Two #antiaging novel biologics/peptides: - TheraVac-AA-1: novel peptide involved in the #ShelterinComplex at #telomeres (see above). - TheraVac-AA-2: novel peptide involved in the RNA interference (#RNAi). - One #MPOX vaccine: TheraVac-MPOX-1. A novel biologics targeting two of the most promising genes/proteins amongst the the six genes/proteins involved in MPOX pathogenesis, including #Clade1b. These proteins play critical roles in the virus's ability to infect host cells by expanding its host range and contributing to immune evasion mechanisms, making them prime candidates for therapeutic interventions." 2️⃣ One #anti-cancer: TheraVac-AC-1. A small molecule, an amidobenzoic acid, that’s taking aim at #telomerase (inhibitor), a critical enzyme in #cancer progression.

I am pleased to extend an invitation to you for the 2024 ISPE Biotechnology Conference, taking place in Boston, Massachusetts, USA, and virtually. This conference is set to be a transformative event, offering a comprehensive exploration of key areas and advancements in biotechnology that are shaping the future of our industry.  Join us as we delve into essential topics that lie at the intersection of innovation and regulation, including: Artificial Intelligence (AI): Learn how AI is helping optimize biotech manufacturing processes, especially in innovative fields like ATMPs and gene therapy. Data Science-Assisted Tech Transfer: Discover how data science is facilitating biopharmaceutical technology transfer while meeting regulatory compliance standards. Sustainability: Examine strategies to enhance environmental sustainability in the biopharmaceutical industry while aligning with global standards. Quality and Regulatory: Understand the importance of digitalized quality management in maintaining regulatory compliance and ensuring supply chain reliability. Novel Technology Innovations: Explore cutting-edge advancements in biopharmaceutical manufacturing that meet rigorous regulatory requirements. Lifecycle Strategies: Discuss strategies to expedite commercialization and refine product life cycle management. Facility Design: Examine trends and regulatory mandates in biopharmaceutical facility design to ensure adherence to industry standards. Additionally, gain valuable insights from industry leaders and regulators who will share their perspectives on the future of pharmaceuticals throughout the conference.

In what key areas can mass spectrometry-based #proteomics and #metabolomics add insight value for drug development? In a recent interview with PharmaShots, Sapient's Dr. Jonathan Usuka shares examples of how these approaches are being applied across phases, from early discovery including target identification and high throughput drug screening to preclinical translation and in #clinicaltrials. Watch the clip below and access the full video to hear more: https://lnkd.in/gACSMepi

Leaders at Pfizer, Moderna, and FogPharma say #mRNA and a new view of precision medicine have sped up biopharma drug development. If you partner that with the flood of funding and #biopharma interest in #AI and #ML, we will hopefully see more and more therapeutics make it to the Clinic and (eventually) the market. https://lnkd.in/eYGpJ2it

One of the biggest challenges in biotech today is that R&D work is largely done with monolithic, internal infrastructure that changes slowly. Biotech companies want to develop a new therapeutic, plant trait, animal free meat, or other amazing product so they grab the tools of the day and get to work. Those tools typically haven’t changed a ton in the last 20 years. Lab work is still largely done by hand with the same pipettes I used in graduate school, with similar kits for common molecular biology protocols, using similar lab equipment, etc. In other industries (like software) the tools of product development are unrecognizable from 20 years ago — vastly more powerful and easy to use. In part that is because the software industry has a flourishing service industry for tools. Things like AWS, Google Cloud and other cloud microservices. Today we’re hoping to take a step in this direction for the biotech industry to help catalyze a flourishing cloud services industry with our Technology Network. More to come but we’d love to see 100s of cloud service providers innovating at the tool level so all the biotech product companies get products out faster with higher likelihood of success. You all deserve better tools !! 🛠️🧬 Also so excited to add the wonderful technology and teams of Proof, Reverie, and Patch to our core infrastructure at Ginkgo!!

our mission at Ginkgo Bioworks, Inc. is to make biology easier to engineer. that doesn’t change! but we don’t have our own product portfolio at Ginkgo. on the cell engineering side of the house, our products are the R&D services we provide to customers - that’s our job as a platform: to create value for our customers growing products with biology, whatever step they’re at, from discovery to optimization to production today’s announcement of TechNet and the inaugural cohort of 25+ partners shows that platform logic at work like Jason Kelly makes clear, you don’t get the GDP of the internet to where it’s at today without a cloud services industry that can provide the infrastructure, unlocking developers to make products at the speed of the actual technology the success of cloud services and microservice architecture, esp today, is worthy inspiration for biology: - if you’re an ai app designer, you don’t pay to build the data center (or the fusion reactor to power it 🤞), you pay for the compute as you need it - as an app developer, architecting an app to be compatible with many services makes a hell of a lot more sense than recreating those services from scratch or writing a structure that makes adding new technologies really difficult - you’ll want to use services which are modular and scalable and integrable with each other and new technologies as they emerge, which allow for continuous deployment and redundancy and optimizability in biology, achieving economies of scale for R&D is hard! but that’s what Ginkgo Bioworks, Inc. has been doing for 15 years at absolutely massive scale: building a platform that allows app developers using biology to bring together scalable services, whether they’re making food or medicine or materials or biosensors or anything else in the age of ai and automation, biotech deserves a true platform today, with a set of incredible partners that i can’t wait to see grow, we took one more step toward that vision

Thrilled to be an inaugural partner with Ginkgo Bioworks, Inc. Technology Network! Catena's selective enzymatic conjugation approach has already enabled the creation of incredible new therapeutic structures with a diverse array of compounds including antibodies, toxins, isotope chelators, nucleic acids, peptides, enzymes, cytokines, VHH, and even whole cells. This partnership further validates Catena's ability to create novel therapeutics that biology alone cannot. Catena's internal pipeline is poised to disrupt the ADC space by enabling multiple payloads on a single antibody along with flexibility of several conjugation sites per antibody. Coupled with superior stability, this creates a targeted combination approach that can deliver potent efficacy with superior toxicity profile to address significant unmet needs in the ADC market. Moreover, Catena’s technology allows for the attachment of payloads far beyond the small molecules used in today’s ADCs. https://lnkd.in/gwywmuvD Saurabh Johri Rick Kendall Marco Lobba, Ph.D.